PTC Therapeutics, Inc. - Common Stock — Filings & Documents (NASDAQ:PTCT) — Page 23 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

2013

Quarterly report, Q2 FY2013

PTC THERAPEUTICS, INC. quarterly report, Q2 FY2013

News

RBC Capital Maintains Sector Perform on PTC Therapeutics, Lowers Price Target to $75

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137

ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?

PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential (NASDAQ:PTCT)

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Top 3 Health Care Stocks You'll Regret Missing This Quarter - PTC Therapeutics (NASDAQ:PTCT), Legend Biot

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript